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methylenetetrahydrofolate reductase locus in human
ovarian carcinomas
A Viel1, L Dall'Agnesel, F Simone1, V Canzonieri2, E Capozzil, MC Visentin3, R Valle1 and M Boiocchi1
Divisions of 'Experimental Oncology 1, 2Pathology, and 3Department of Gynaecological Oncology, Centro di Riferimento Oncologico, 33081 Aviano, Italy
Summary The high-affinity folate-binding protein (FBP) is primarily involved in the uptake of the 5-methyltetrahydrofolate, and its expression
may be physiologically regulated by the intracellular folate content. The overexpression of FBP on the cell surface of ovarian carcinoma
cells may be responsible for an increased folate uptake. We tested the hypothesis of the existence of a defect in the 5, 10-
methylenetetrahydrofolate reductase (MTHFR) in ovarian tumours that could cause reduced intracellular regeneration of the 5-
methyltetrahydrofolate and induce increased FBP expression. No sequence mutations were found in the MTHFR gene, but allelic deletions of
this gene were frequently detected in ovarian tumours (59%). Chromosomal losses appeared to be confined to the 1p36.3 region to which the
MTHFR gene maps. Although it cannot be stated that MTHFR is the target gene of the chromosomal loss involving the 1p36.3 region, a
correlation between loss of heterozygosity at this locus and decrease in MTHFR activity was shown, suggesting a role of these allelic
deletions in generating a biochemical defect in folate metabolism. Further studies are needed to assess further the relationship between
MTHFR and FBP overexpression, but the demonstration of the alteration of a key metabolic enzyme of the folate cycle in a subset of human
ovarian tumours is in accordance with the hypothesis of an altered folate metabolism in these neoplasias and might be exploited for
therapeutic purposes.
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Folates are a class of pteridine compounds essential for normal
growth and maturation, as they are involved in one carbon atom
transfer reactions, such as those necessary for the biosynthesis of
methionine, deoxythymidylic acid and purines (Shane, 1989).
Taking part in these metabolic pathways, folate co-enzymes are
interconverted and, therefore, cellular folate uptake is only
required to replace natural coenzyme degradation and to re-estab-
lish the physiological pool when cells undergo mitosis.
High-affinity folate-binding proteins (FBPs) are glycosylphos-
phatidylinositol (GPI)-linked membrane proteins relevant to
cellular folate uptake (Henderson, 1990; Antony, 1992). Two
isoforms, a- and ,3-FBP, were originally identified in human
epidermoid carcinoma cells and normal placenta. j-FBP is gener-
ally expressed in low to moderate amounts in normal tissues. a-
FBP, which is recognized by the monoclonal antibody MOv18, is
moderately expressed in some normal epithelial cells butis present
at higher levels in very specialized organs, such as normal
fallopian tubes, adult renal proximal and distal tubules and
lactating glands. Moreover, a-FBP is overexpressed in a variety of
neoplastic tissues, particularly in non-mucinous ovarian carci-
nomas (80%) and adenomas (approximately 100%), whereas
normal ovary, uterus and vagina are negative (Miotti et al, 1987;
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Veggian et al, 1989; Campbell et al, 1991; Coney et al, 1991; Ross
et al, 1994). Such aphenotypic characteristic, although not limited
to ovarian carcinomas, may suggest that these neoplastic cells
have an increased metabolic requirement for folates, the uptake of
which can be highly intensified by an increased expression of the
high-affinity FBP receptor molecules.
The mechanismby which FBP expression is elevated in ovarian
carcinomas does not appear, in general, to involve gene amplifica-
tion, but it may possibly be ascribed to the transcriptional regula-
tion of the gene (Campbell et al, 1991). It is well known that in
several cases FBP expression is physiologically regulated by the
intracellular folate content (Kamen and Capdevila, 1986; Kane et
al, 1988; Matsue et al, 1992; Miotti et al, 1995), most probably by
the 5-methyltetrahydrofolate (5-CH3-H4 folate) content, since this
coenzyme is the natural ligand ofFBP and represents the predom-
inant circulatory form (>90% of the overall seric folate, under
physiological conditions) (Antony, 1992). Intracellular 5-CH3-H4
folate shortage may be consequent on limited bioavailability of
extracellular folates or on biochemical defects in the intracellular
regeneration or cellularretention ofthis folate form.
Since there was no evidence of low folate seric concentrations
in patients with ovarian carcinomas (manuscript in preparation),
we wondered which special condition exists in these tumours that
selectively increases the demand for folates, as suggested by the
overexpression of FBP. We focused our attention on the 5, 10-
methylenetetrahydrofolate reductase (MTHFR), the enzyme that
catalyses the intracellular regeneration of the 5-CH3-H4 folate
(Matthews, 1986). Lack or reduced activity of MTHFR, in fact,
will cause shortage of the intracellular content of the 5-CH3-H4
folate and possibly induce the physiological up-regulation of the
FBP expression.
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Table 1 Primers for MTHFR SSCP analysis
Positiona Sequenceb bpc Annealing
temperature (OC)
-4 CGGAGCCATGGTGAACGAAGCC 211 60
207 TCGAGGAGGGAAGAATTCCAGGG
161 TGGAATCTGGTGACAAGTGGTT 205 57
365 CCACAGTAGTTCACGGCGGT
299 GTGACCCTGGCTCAGACAAG 267 57
565 CACCAAACTCACTTCGGATG
510 GGGAGGCTTCAACTACGCAG 292 57
801 CCGAAGGGAGTGGTAGCC
746 TCACTTGCCCCATCGTCC 291 59
1036 GCCTGGGGTCCTCGGTC
953 AGAGGTGCTGAAGCGCCTGGGG 260 62
1252 GCTCCTCCTTGGGGGACTTGCT
1187 CTGCCTTTGGGGAGCTGAA 285 58
1471 CGTTGATGTTGGGCTGTGAG
1431 CCAGGGCATCCTCACCATCA 304 67
1734 GGGATCCACTACGGTGGGCT
1693 TTCCCTGGGCGAGAGATCAT 293 67
1985 AGGACGCAGGGTCATGGAG
1940 CCACCCAGAATGCGAGAGAA 245 65
2184 AGCAGAGAGTACTAGGTTCCCA
aPositions, corresponding to 5' end of primer, refer to MTHFR cDNA
sequence no. U09806. bFor each primer pair, the first oligonucleotide
represents the forward primer, and the second corresponds to the reverse
primer. cLength of the PCR products.
MATERIALS AND METHODS
Patients and tissue samples
This study considered 89 patients with non-mucinous ovarian
carcinoma who underwent surgery at the Department of
Gynaecological Oncology at our centre. Tumour samples were
obtained immediately after surgery and were selected at the
Division of Pathology by a pathologist such that representative
tissue sampling was routinely associated with sampling of adja-
cent tissue blocks for microscopic control examination. Peripheral
blood lymphocytes or normal abdominal tissues ofeach individual
were used as a source ofnormal DNA.
Five human ovarian tumour cell lines (SK-OV-3, SW 626,
Caov-3, Caov-4 and NIH:OVCAR-3), obtained from the
American Type Culture Collection (Rockville, MD, USA), were
also introduced in this study.
FBP expression
To determine the pattern of tumoral expression of FBP, 24
randomly chosen non-mucinous ovarian carcinomas were tested
with the monoclonal antibody (MAb) MOv18 (kindly supplied by
Dr S Miotti, Istituto Nazionale per lo Studio e la Cura dei Tumori,
Milan, Italy). Cryostat sections were used forimmunophenotyping
with MOv18, by the avidin-biotin peroxidase complex (ABC)
method, as described previously (Hsu et al, 1981).
Reverse transcriptase polymerase chain reaction
(RT-PCR) and single-strand conformation
polymorphism (SSCP) procedures
Total RNA was extracted by the guanidinium thiocyanate-
phenol-chloroform method (Chomczynsky and Sacchi, 1987) from
ovarian tumour tissues and cell lines. cDNA was synthesized with
the AMV reverse transcriptase (Promega, Madison, WI, USA)
using random hexamers and then amplified by PCR. Primers listed
in Table 1 were designed from the cDNA sequence according to
numeration deposited in GenBank no. U09806 (Frosst et al, 1995).
In a first amplification round, two longerPCRproducts (fromposi-
tion -4 to 1252 and from 1187 to 2184) were obtained. An aliquot
of the first PCR was then reamplified to generate ten overlapping
205-304-bp fragments spanning from position -4 to 2184. Radio-
active PCR and SSCP analyses were carried out as described previ-
ously (Viel et al, 1995).
Southern blotting
High molecular weight DNA was purified from ovarian tumours
and normal tissues with an automated nucleic acid extractor
(Applied Biosystems, Foster City, CA, USA). BglII-restricted
DNAs were analysed as described previously (Viel et al, 1990).
Blots were hybridized to a random primer 32P-labelled 1.2-kb
MTHFR probe (portion 5'), which was obtained by RT-PCR from
a normal RNA.
Loss of heterozygosity (LOH) analysis
Restriction fragment length polymorphism (RFLP) and micro-
satellite analyses were performed to search for allelic deletions of
sequences mapping on the short arm (p) of chromosome 1. The
first experimental approach was applied to seek LOHs of the
MTHFR gene. Genomic tumour and normal DNA (250 ng) were
amplified by standard PCR (Viel et al, 1994) in the presence of
5% formamide at an annealing temperature of 510C. The primers
used were: 639, GCACTTGAAGGAGAAGGTGTC and 701,
CAAAGCGGAAGAATGTGTCAG. The 83-bp PCR products
were ethanol precipitated, digested with Taql and run on a 4%
MetaPhor gel (FMC Bioproducts, Rockland, ME, USA). In the
presence of a Taql site, two smaller fragments of 53 and 30 bp
were generated. Loss of or significant reduction (at least 50%) in
the intensity for one allele in the tumour DNA was interpreted as
LOH. A similar analysis (RT-PCR and Taql restriction) was
performed at the RNA level. In this case, tumour and normal
cDNA was amplified by standard PCR (primers -4 and 1252,
annealing temperature 63°C). Taql digestion produced constant
bands of95, 113 and 353 bp, and variable bands of 695 bp (allele
1) or 464 plus 231 bp (allele 2).
Microsatellite analysis was carried out by amplification of the
polymorphic simple repeat regions of the DIS160, DIS170, FGR
and L-myc loci, as described (Patel et al, 1992; Miikela et al, 1992;
Engelstein et al, 1993). PCRs were performed in the presence of
[a-33P]dATP, denatured and electrophoresed on 6% denaturing
polyacrylamide gels (Viel et al, 1995).
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Figure 2 Representative examples of LOH analyses with the repetitive
sequences associated with loci L-myc, FGR, DlS160 and Dl S170. The
genotype of tumour DNAs (T) is compared with that of corresponding normal
DNAs (N). Heterozygous (1) and deleted (2) tumours are shown. Arrowheads
indicate the allele lost in tumour DNA
Figure 1 Representative examples of the molecular analyses that identify
the AlaNal polymorphism at position 668 and detect LOH at the MTHFR
locus. (A) SSCP: tumours with heterozygous (1), deleted (2 and 6) and
homozygous (3-5) genotypes are shown. (B and C) PCR from genomic DNA
(B) and cDNA (C) followed by Taql restriction: allelic bands of 83 bp or 53 bp
plus 30 bp (B), and of 695 bp or 464 bp plus 231 bp (c) are generated. The
dimension of constant bands is indicated in parentheses. The pattern of
tumour DNAs (T) is compared with that of the corresponding normal DNAs
(N). Heterozygous (1), deleted (2 and 3) and homozygous (4 and 5) tumours
are shown. Arrowheads indicate the allele lost in tumour DNA
MTHFR assay
Tumour tissues were pulverized with a dismembrator (Braun,
Milan, Italy). The cells were then completely disrupted by sonica-
tion in 30 mm potassium phosphate buffer (pH 7.2) and
centrifuged at 13 000 g for 60 min. The supematant solution
containing 250 .tg ofprotein was used for the enzyme assay, which
was performed by the 5-CH3-H4folate-menadione oxidoreductase
method described elsewhere (Matthews, 1986), with some modifi-
cations. Briefly, the reaction mixture, in a total volume of 0.5 ml,
consisted of 50 mm potassium phosphate buffer (pH 6.7), 0.3 mM
EDTA, 0.33% bovine serum albumin (BSA), 10% menadione
(from a saturated solution in 20% methanol) and 0.25 mM 5-
['4C]methyl-tetrahydrofolic acid (Amersham, Buckinghamshire,
UK). After incubation for 1 h at 37°C, the reaction was terminated
by adding 0.15 ml of a 3-mg ml- dimedone solution and then
boiled for 5 min. The mixtures were cooled on ice and the
produced ['4C]formaldehyde-dimedone complex was extracted
into 1.5 ml oftoluene and dosed by scintillation counting. MTHFR
activities were expressed in nmol of ['4C]formaldehyde h-I mg-1
protein.
RESULTS
FBP expression
As expected, all the tumours tested were positive for FBP expres-
sion. A variable proportion of tumour cells ranging from 25% to
100% was stained with MOvl8 (MAb), with a positivity lower
than 50% in seven cases and higher than 50% in 17 other cases
(data not shown).
Mutational analysis of the MTHFR gene
Total RNA of 18 human ovarian carcinomas and five ovarian
carcinoma cell lines was analysed by the RT-PCR/SSCP method.
Thirteen of these 18 tumour samples were chosen from among
those retaining only one allele at the MTHFR locus (see below).
No abnormal pattern suggestive of sequence mutations was found.
However, the C/Tpolymorphism at nucleotide 668 (butreported as
nucleotide 677 in the article by Frosst et al, 1995), which converts
an alanine (Ala) to a valine (Val) and creates a Taql RFLP, was
detectable by this method (Figure 1). Analysis of this polymor-
phism at the DNA level by PCR and Taql restriction (Figure 1)
showed frequencies of the allele for Val that were similar in 58
healthy blood donors (45%) and 89 ovarian carcinoma patients
(47%). The frequency ofthe three genotypes was also superimpos-
able in these two populations (Ala-Ala, 28% and 29%; Ala-Val,
48% and 50%; Val-Val, 23% and 22% respectively). Another
common C/A polymorphism was identified at nucleotide 1289.
It converts an Ala to a glutamic acid, creating an MboII site (data
not shown). Finally, two sequence variations were identified at
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Figure 3 Summary of allelic losses in 59 ovarian tumours. The top row lists
the loci studied and their chromosomal location, but the reciprocal order of
the three polymorphic sequences mapping on band 1p36.3 is not known.
On the left, the numbers of tumours displaying each pattern are indicated.
U, Heterozygous;EM, LOH; El, non-informative or not tested
positions 120 and 1059 (C instead ofT), which probably represent
two silent polymorphisms distinguishing the Italian from the
American population. In fact, we found the wild-type sequence
only in an ovarian cancer patient who came from the USA.
BglIl-DNA digestion and Southern hybridization to a 1.2-kb
MTHFR cDNA probe did not show anomalous restriction frag-
ments in the five ovarian tumour cell lines and the ten tumour
samples analysed (data not shown).
LOH analysis
The Taql RFLP of the MTHFR gene (mapping on chromosome
lp36.3) was used to search for allelic deletions in 89 ovarian carci-
nomas. The frequency of heterozygous informative patients was
49% (44/89). The analysis showed LOH at the MTHFR locus in a
total of 26 tumours (59% of the informative cases). Of these, 11I
displayed partial or total loss ofthe allele for Val and were defined
as 'LOH Ala' because they retained the Ala allele; the other 15
deleted tumours, which lost the allele for Ala partially or totally
and retained the allele for Val, were defined as 'LOH Val' (Figure
1). A similar analysis at the RNA level (RT-PCR and TaqlI restric-
tion) confirmed these data in the 25 informative tumours tested
(Figure 1). Seven tumours of the LOH Ala group and six tumours
ofthe LOH Val group were also submitted to mutational screening
by the RT-PCR/SSCP method.
Table 2 Relationship between MTHFR activity and MTHFR genotype
Tumour MTHFR activity MTHFR activity Statisticsd
genotype (n)a (mean ± s.d.)b (%)c
Ala-Ala (14) 16.50 ± 9.20 100
Val-Val (12) 7.19 ± 3.90 44 P=0.001
Ala-Val (9) 11.63 ± 4.76 70
LOH Val (14) 5.82 ± 3.63 35 P=0.011
Ala-Val (9) 11.63 ± 4.76 70
LOH Ala (5) 10.06 ± 3.16 61 NS
aNumber of tumours tested. bExpressed in nmol of [14C]formaldehyde h-1 mg-'
protein. cPercentages are calculated with respect to the activity of Ala-Ala
tumours. dStatistical significance was assessed by the Mann-Whitney U-test.
NS, not significant.
In 59 tumours, LOH analysis was extended to other polymor-
phic sequences mapping on the short arm of chromosome 1
(Figure 2). Fifty-seven samples proved to be informative at one or
more loci; altogether, 54% of them exhibited LOH in at least one
locus on lp (Figure 3).
The CA repeats associated with theDIS160 and DISJ 70loci on
lp36.3 were amplified by PCR according to Engelstein et al
(1993), and the observed LOH frequencies were similar to those of
the MTHFR gene (52% and 50% respectively). A good concor-
dance in the allelic losses of these polymorphic regions mapping
on lp was noted; in fact, DJS160 and DIS170 LOHs were not
detected in MTHFR heterozygous tumours and only one MTHFR-
deleted tumour retained both DIS170 alleles. The polymorphism
associated with the FGR gene on lp36.1-2 (Patel et al, 1992)
showed that heterozygosity was maintained in four cases
displaying allelic losses at the above-mentioned loci. The lowest
percentage of LOH was detected by the analysis of the AAAG
repeat polymorphism upstream L-myc (lp32) (Miikela et al, 1992)
on 46 informative cases (9/46; 20%). All the MTHFR heterozy-
gous tumours also maintained heterozygosity at the L-myc locus;
in contrast, of the cases with MTHFR LOH, eight retained both
alleles of L-myc and only four showed LOH at this locus. This
pattern suggested that in the majority of the cases the chromo-
somal loss was telomeric.
MTHFR activity in ovarian carcinomas
The MTHFR activity was assayed in the crude extracts from 54
human ovarian carcinomas. Each test was carried out in triplicate
and some tumours were tested twice, with reproducible results.
The mean activity value was 10.25 + 7.02 nmol of [14C]formalde-
hyde h-' mg-' protein. No activity was found in two cases (7%).
Goodquality RNAs were successfully extracted from these tumours
(kept at-800C) as a guarantee oftheirgood preservation. The other
tumours showed a variable enzyme activity, ranging from
0.58-42.38 nmol of[1'4C]formaldehyde h-I mg-' protein.
Therelationship between MTHFR activity andMTHFR genotype
was studied (Table 2). The Ala-Ala homozygous tumours had the
highest activity, with a mean value of 16.50 ± 9.20. In contrast, the
Val-Val homozygous tumours displayed a low activity, with a mean
of 7.19 + 3.90. The Mann-Whitney U-test attributed a statistical
significance to this distribution (P=0.001). Ala-Val heterozygous
tumours exhibited an intermediate level (11.63 ± 4.76). Loss ofone
allele was proportionally associated with a decrease in MTHFR
activity, with mean values of 10.06 ± 3.16 in the informative
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tumours showing loss ofthe Val allele (LOH Ala) andof5.82 + 3.63
in the cases displaying loss ofthe Ala allele (LOHVal). Comparison
of heterozygous with deleted tumours showed that loss of the Ala
allele, but not the Val allele, was associated with a significant
decrease in MTHFR activity (P=0.011).
DISCUSSION
MTHFR catalyses the reduction of 5,10-methylenetetrahydrofo-
late to 5-CH3-H4 folate, the predominant circulatory form of
folates and carbon donor for the remethylation ofhomocysteine to
methionine. The MTHFR human gene has been localized to chro-
mosome lp36.3 (Goyette et al, 1994) and codifies for a polypep-
tide of77 kDa, which forms homodimers ofabout 150 kDa (Zhou
et al, 1990). Two functional alleles of MTHFR have been identi-
fied in the human population because of a C to T substitution at
nucleotide 668, which converts Ala residues into Val residues
(Frosst et al, 1995). The allele frequency of the substitution was
0.38 in a series of 114 French-Canadian chromosomes (Frosst et
al, 1995), 0.45 in 58 Italian normal blood donors and 0.47 in 89
Italian ovarian cancer patients (this study). The similar genotype
frequencies at the MTHFR locus in the Italian healthy and affected
populations suggest thattheMTHFR genotype does notrepresent a
risk factor in ovarian carcinogenesis.
Southern blot and SSCP analyses performed on a sample of
ovarian carcinoma tissues and cell lines did not show any signifi-
cant structural alterations ofthe MTHFR gene either in the portion
codifying for the catalytic and substrate-binding sites or in that
codifying for the regulatory sequences (Goyette et al, 1994; Frosst
et al, 1995). However, our molecular analysis confirmed the exis-
tence of the above-mentioned AlaNal allelic polymorphism
(Frosst et al, 1995). Comparison ofthe genotype oftumour tissues
with peripheral leucocytes ofovarian carcinomapatients identified
44 heterozygous patients, ofwhom 26 (59%) displayed deletion of
oneMTHFR allele at the tumour level (15 lost the Alaallele and 11
lost the Val allele). Such a LOH was confirmed by the analysis of
two polymorphic sequences, DIS160 and DIS170, which map
near the MTHFR locus on the same lp36.3 chromosome band
(Engelstein et al, 1993); however, chromosomal losses did not
extend, except in a few cases, to the lp32 band, at which the L-myc
locus maps (Miakela et al, 1992). On the whole, more than 50% of
the ovarian carcinomas showed LOH in at least one of the three
polymorphic markers mapping in lp36.3, as a consequence of
chromosomal deletions always including one allele ofthe MTHFR
gene. This high incidence of LOH in lp has not been described
previously in LOH studies performed on human ovarian carci-
nomas with other polymorphic sequences on chromosome lp
(Sato et al, 1991; Chenevix Trench et al, 1992; Yang Feng et al,
1993; Cliby et al, 1993; Osborne and Leech, 1994), but is in accor-
dance with previous cytogenetic studies indicating a high
frequency of structural abnormalities involving the region lp36
(Jenkins et al, 1993; Thompson et al, 1994).
Our data therefore support the existence ofa gene in 1p36.3 the
deletion ofwhich might be implicated in the oncogenic process of
a significant proportion of ovarian carcinomas. Whether this gene
is the MTHFR has to be verified. The MTHFR gene, although
undergoing LOH in more than 50% of the ovarian carcinomas,
does not completely lose its function, since no inactivating muta-
tions were detected in the retained allele of 13 deleted tumours, as
well as in five other MTHFR non-informative tumours and five
ovarianl car-cinoma cell lines.
However, a functional effect at the level of cellular metabolism
may be consequent to LOH at the MTHFR locus. The MTHFR
alleles are concomitantly expressed in peripheral lymphocytes and
ovarian carcinomas not affected by LOH at this locus, and reduced
gene dosage is expected to cause a decrease in MTHFR enzymatic
activity in tumours with LOH. In fact, although a considerable
variability in MTHFR activity was seen in the ovarian carcinomas
tested, with the highest activity in Ala-Ala homozygotes and the
lowest activity in Val-Val homozygotes, the tumours affected by
LOH at this locus displayed lower enzymatic activity levels than
tumours of patients with the same genotype but not affected by
LOH at lp36.3.
It has been reported recently that there is a close relationship
between the MTHFR genotype and the capability to remethylate
homocysteine to methionine, demonstrating that a low MTHFR
activity may really be responsible for reduced intracellular
bioavailability of5-CH3-H4 folate (Frosst et al, 1995). Moreover, in
conditions ofshortage of5-CH3-H4 folate, the cell can physiologi-
cally up-modulate FBP expression in order to increase coenzyme
uptake from the extracellular fluids (Kamen and Capdevila, 1986;
Kane et al, 1988; Matsue et al, 1992; Miotti et al, 1995). Therefore,
at least for the subset ofovarian carcinomas displaying LOH at the
MTHFR locus, our working hypothesis seems to be confirmed,
even ifnot directly proved. The reason is that the semi-quantitative
determination of FBP expression, provided by the immunohisto-
chemical technique, did not allow a statistical correlation between
MOvl8 positivity and MTHFR genotype and enzymatic activity.
However, it should be pointed out that LOH at the MTHFR locus
was not detected in three informative tumours of the mucinous
histotype, which is usually MOvl8 negative (data not shown).
The finding that FBP overexpression may also occur in ovarian
carcinomas not displaying LOH at the MTHFR locus remains an
open question, although other alterations in the folate cycles might
be involved, possibly exerting a similar influence on folate metab-
olism and FBP expression. Studies on this topic are under way.
In conclusion, alteration of a gene coding for a key metabolic
enzyme of the folate cycle, and more precisely the methionine
cycle, has been demonstrated in a significant subset (59%) of
human ovarian carcinomas. This should make possible the design
of new therapies that take advantage of metabolic differences
between ovarian tumour cells and normal cells. In particular, a
possible relationship between MTHFR deficiency and methionine
dependence has been proposed (Jacobsen et al, 1977), since
MTHFR-defective cells are unable to synthesize 5-CH3-H4 folate
at a rate that will satisfy the cellular demand for methionine. Such
an alteration might represent a target for specific therapies, as
suggested by previous studies on methionine-dependent tumours
(Hoffman, 1984; Goseki et al, 1992; Guo et al, 1993).
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